Abstract
Persons living with HIV/aids, organ transplanted and other immunocompromised individuals have high risk of HPV persistent infection and HPV-related cancers. A previous open label trial, conducted by the authors, evaluated vaccine safety and primary antibody response (one month after the third does) of the HPV quadrivalent vaccine (HPV4v) in 18- to 45-year-old women using immunosuppressors…